Hologic, Inc. (NASDAQ:HOLX) – Analysts at Piper Jaffray Companies cut their Q2 2019 earnings per share (EPS) estimates for Hologic in a note issued to investors on Tuesday, October 16th, according to Zacks Investment Research. Piper Jaffray Companies analyst W. Quirk now expects that the medical equipment provider will earn $0.61 per share for the quarter, down from their prior forecast of $0.62. Piper Jaffray Companies has a “Overweight” rating and a $45.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Hologic’s FY2019 earnings at $2.57 EPS and FY2020 earnings at $2.84 EPS.
Several other equities analysts have also issued reports on HOLX. Deutsche Bank boosted their price target on shares of Hologic from $42.00 to $45.00 and gave the company a “hold” rating in a report on Wednesday, August 1st. BidaskClub lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 25th. Cowen reissued a “buy” rating and issued a $45.00 price target on shares of Hologic in a report on Wednesday, August 1st. Canaccord Genuity reissued a “hold” rating and issued a $43.00 price target on shares of Hologic in a report on Thursday. Finally, TheStreet raised shares of Hologic from a “c” rating to a “b” rating in a report on Tuesday, July 31st. One research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $44.41.
Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, November 7th. The medical equipment provider reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.01). Hologic had a positive return on equity of 22.93% and a negative net margin of 3.46%. The business had revenue of $813.50 million for the quarter, compared to analyst estimates of $808.63 million. During the same period in the prior year, the firm posted $0.50 EPS. Hologic’s revenue was up 1.3% on a year-over-year basis.
A number of large investors have recently modified their holdings of the business. BlackRock Inc. lifted its position in Hologic by 0.9% during the 3rd quarter. BlackRock Inc. now owns 18,773,720 shares of the medical equipment provider’s stock worth $769,349,000 after buying an additional 164,937 shares in the last quarter. Parnassus Investments CA raised its holdings in shares of Hologic by 3.4% in the 2nd quarter. Parnassus Investments CA now owns 16,241,334 shares of the medical equipment provider’s stock valued at $645,593,000 after purchasing an additional 535,745 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Hologic by 5.1% in the 2nd quarter. Victory Capital Management Inc. now owns 5,813,464 shares of the medical equipment provider’s stock valued at $231,085,000 after purchasing an additional 282,510 shares during the period. FMR LLC raised its holdings in shares of Hologic by 6.4% in the 3rd quarter. FMR LLC now owns 2,438,184 shares of the medical equipment provider’s stock valued at $99,916,000 after purchasing an additional 146,726 shares during the period. Finally, Partner Fund Management L.P. raised its holdings in shares of Hologic by 20.3% in the 2nd quarter. Partner Fund Management L.P. now owns 1,892,703 shares of the medical equipment provider’s stock valued at $75,235,000 after purchasing an additional 319,846 shares during the period. 98.74% of the stock is currently owned by hedge funds and other institutional investors.
In other Hologic news, Director Sally Crawford sold 13,257 shares of the business’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $39.54, for a total transaction of $524,181.78. Following the sale, the director now directly owns 167,701 shares of the company’s stock, valued at approximately $6,630,897.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Christiana Stamoulis sold 30,967 shares of the business’s stock in a transaction dated Tuesday, October 2nd. The stock was sold at an average price of $40.70, for a total transaction of $1,260,356.90. Following the sale, the director now directly owns 66,006 shares in the company, valued at $2,686,444.20. The disclosure for this sale can be found here. Insiders sold a total of 49,519 shares of company stock worth $2,003,965 over the last ninety days. 0.79% of the stock is currently owned by insiders.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Further Reading: What is a stock split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.